Dabrafenib plus trametinib, a type of MEK inhibitor, when given in combination to NSCLC patients bearing the BRAF V600E mutation, has shown an ORR of 64%, PFS of 14.6 months and an OS of 24.6 months [32,33]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.